Evaluation of E-Cadherin Expression in Gastric Cancer and Its Correlation with Clinicopathologic Parameters
Background: Gastric cancer is one of the most common cancers in the world. There are many genomic and molecular factors that cause gastric cancer to occur. Also, many markers that associate with tumor invasiveness have been known.
E-Cadherin is a calcium- mediated cell adhesion molecule. In some studies, abnormal expression of E-Cadherin has been seen in gastric carcinoma. However, in the studies done there has been some conflicting information about abnormal expression of this marker in a variety of gastric carcinoma and also about the expression of this marker and its correlation with various clinicopathologic factors of tumor.
Subjects and Methods: A case control study was performed on total or partial gastrectomy tissue samples obtained from 70 patients with gastric cancer and adjacent non-neoplastic tissues. The immunohistochemistry was used to assess E-Cadherin expression. The correlation between abnormal E-Cadherin expression and tumor histopathology was evaluated in all patients.
Results: Among 70 patients who were analyzed, 48.6% showed abnormal E-Cadherin expression. A significant correlation was seen between abnormal E-Cadherin expression and tumor stage, grade, lymph node metastasis, tumor phenotype, tumor type, depth of invasion and age.
Conclusion: Abnormal E-Cadherin expression is a common phenomenon in gastric cancer. Because there was a strong correlation between abnormal E-Cadherin expression and tumor stage, tumor grade, depth of invasion and regional lymph node involvement, this marker may be used as a predictive factor for tumor invasiveness in gastric cancer.
Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC cancer. 2010; 10(1):218.
Rocco A, Compare D, Nardone G. Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. World Journal of Gastrointestinal Oncology. 2012; 4(3):54.
Taghavi N, Nasrollahzadeh D, Merat S, et al. Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases. World Journal of Gastroenterology: WJG. 2007; 13(40):5367-7.
Mousavi S, Alamolhoda A, Gouya M, et al. Implementation of Comprehensive National Cancer Control Program in Iran: an experience in a developing country. Annals of Oncology. 2008; 19(2):398-400.
Mohebbi M, Mahmoodi M, Wolfe R, et al. Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: spatial analysis of cancer registry data. BMC cancer. 2008; 8(1):137.
Movahedi M, Afsharfard A, Moradi A, et al. Survival rate of gastric cancer in Iran. Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences. 2009; 14(6):367.
Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009; 12(6):576-83.
Jang BI, Li Y, Graham DY, et al. The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer. Gut and liver. 2011; 5(4):397-405.
Rosai J. Rosai and Ackerman's Surgical Pathology, 10e: Elsevier Health Sciences, 2011.
Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003; 5(6):R217-R22.
Wang L, Li Z, Wang C, et al. E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating Bcl-2 expression. Archives of Biochemistry and Biophysics. 2009; 481(1):116-22.
Berezhnaya N, Belova O, Vinnichuk YD, et al. Expression of E-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action. Experimental Oncology. 2009; 31(4): 242-5.
Zhu Y, Wu J, Ma W, et al. Expression of TGF-β1, Snail, E-cadherin and N-cadherin in Gastric Cancer and Its Significance. Chinese Journal of Clinical Oncology. 2007; 4(6):384-9.
Canavese G, Bernardi A, Candelaresi G, et al. Expression of the E-cadherin–catenins complex in sentinel node is related to tumor morphology but not to spread to nonsentinel nodes. Pathology-Research and Practice. 2007; 203 (7):517-23.
Ramos-Vara J. Technical aspects of immunohistochemistry. Veterinary Pathology Online. 2005; 42(4):405-26.
Ramos-Vara J, Miller M. When Tissue Antigens and Antibodies Get Along Revisiting the Technical Aspects of Immunohistochemistry-The Red, Brown, and Blue Technique. Veterinary Pathology Online.2014; 51(1):42-87.
Chu Y-Q, Ye Z-Y, Tao H-Q, et al. Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World Journal of Gastroenterology: WJG. 2008; 14(13):1990.
DeVita Jr VT, Rosenberg SA. Two hundred years of cancer research. New England Journal of Medicine. 2012; 366(23):2207-14.
Halpering E, Perez CA, Brady L. Principles and Practice of radiation Oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.
Anbiaee R, Sheibani KM, PeymanTorbati HJ. Abnormal expression of e-cadherin in gastric adenocarcinoma, and its correlation with tumor histopathology and helicobacter pylori infection. Iranian Red Crescent Medical Journal. 2013; 15(3):218.
Lazăr D, Tăban S, Ardeleanu C, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008; 49(4):459-67.
Saad AA, Awed NM, Elkerim NNA, et al. Prognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patients. Annals of Surgical Oncology. 2010; 17(11):3059-67.
Micu G, Staniceanu F, Zurac S, et al. E-cadherin and β-catenin Expression in Gastric Neoplastic and Non-Neoplastic Lesions–Correlations with H. Pylori Infection. Rom J Intern Med. 2010; 48(3):271-80.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.